Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mometasone furoate
Drug ID BADD_D01491
Description Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295]. It has a glucocorticoid receptor binding affinity 22 times stronger than [dexamethasone] and higher than many other corticosteroids as well[A176906]. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295].
Indications and Usage There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 years[FDA Label]. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years, treating nasal polyps in patients ≥18 years, and prophylaxis of seasonal allergic rhinitis in patients ≥12 years[F4292]. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years[F4295].
Marketing Status approved; investigational; vet_approved
ATC Code R03BA07; D07XC03; R01AD09; D07AC13
DrugBank ID DB14512
KEGG ID D00690
MeSH ID D000068656
PubChem ID 441336
TTD Drug ID D03HYX
NDC Product Code 11517-222; 51927-4506; 62991-3098; 0113-1720; 50090-1633; 51672-1311; 63187-432; 63629-9306; 0713-0701; 46439-8733; 63592-0397; 75895-0279; 75895-0280; 0168-0270; 0168-0272; 70518-3244; 0713-0634; 78206-113; 38779-2413; 63190-0730; 45802-257; 50090-2991; 60429-664; 63629-8686; 60505-0830; 63187-288; 68462-192; 63190-0340; 64918-0330; 50090-1025; 63629-8682; 63629-9305; 68462-225; 11517-434; 51552-1510; 64918-0424; 68788-8357; 10599-003; 53002-8321; 63629-8684; 10695-111; 11517-433; 15308-0220; 50909-5151; 52128-163; 58175-1234; 71161-133; 45802-118; 63629-8681; 63629-8685; 68462-385; 0713-0635; 78206-111; 22552-0002; 63592-0387; 16714-974; 0113-1999; 45802-119; 53002-8320; 63629-8683; 71205-413; 78206-112; 78206-114; 0168-0271; 68788-8345; 78206-115; 53104-7646; 65089-0025; 51672-1305; 51672-1315
UNII 04201GDN4R
Synonyms Mometasone Furoate | Furoate, Mometasone | Nasonex | Mometasone Furoate Monohydrate | Furoate Monohydrate, Mometasone | Monohydrate, Mometasone Furoate | Asmanex Twisthaler | Twisthaler, Asmanex | Asmanex | Rinelon | Elocon | Sch 32088 | Sch-32088 | Sch32088 | Mometasone
Chemical Information
Molecular Formula C27H30Cl2O6
CAS Registry Number 83919-23-7
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Poor quality sleep17.15.04.002; 19.02.05.0050.003368%-
Treatment failure08.06.01.017---
Oropharyngeal pain07.05.05.004; 22.12.03.0160.007232%
Upper-airway cough syndrome22.12.03.036--
Sensitisation08.01.05.009; 10.02.01.012---
Candida infection11.03.03.021--
Complication associated with device08.07.01.0110.003368%-
Frustration tolerance decreased19.04.02.0160.003368%-
Lower respiratory tract congestion22.12.01.004---
Fine motor skill dysfunction17.01.02.020---
Increased viscosity of upper respiratory secretion22.12.03.008---
Administration site laceration08.02.04.026; 12.07.04.026; 23.03.11.024---
Allergic reaction to excipient10.01.01.0350.002179%-
Bell's palsy17.04.03.011---
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.010105%-
Pharyngeal swelling22.04.05.0280.000991%-
Skin laceration12.01.06.016; 23.03.11.041---
Taste disorder07.14.03.004; 17.02.07.029---
Therapeutic product effect decreased08.06.01.0500.008421%-
Therapeutic product effect incomplete08.06.01.0520.011789%-
Therapeutic response shortened08.06.01.062---
The 8th Page    First    Pre   8    Total 8 Pages